$FENC
FENNEC PHARMACEUTICALS INC.

2017 Form 10-K Financial Statement

#000114420418017571 Filed on March 28, 2018

View on sec.gov

Income Statement

Concept 2017 2016 Q4 2016
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.020M $970.0K $2.400M
YoY Change 109.17% 102.08% 47.24%
% of Gross Profit
Research & Development $1.936M $170.0K $472.0K
YoY Change 310.17% 142.86% 84.38%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.936M $1.150M $472.0K
YoY Change 310.17% 109.09% 84.38%
Operating Profit -$6.951M -$2.871M
YoY Change 142.11% 51.9%
Interest Expense -$90.00K $10.00K $60.00K
YoY Change -250.0% -95.12%
% of Operating Profit
Other Income/Expense, Net -$95.00K $0.00 $82.00K
YoY Change -215.85% -100.0% -93.34%
Pretax Income -$7.046M -$1.140M -$2.789M
YoY Change 152.64% 111.11% 323.86%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$7.046M -$1.140M -$2.789M
YoY Change 152.64% 111.11% 323.22%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$469.7K -$83.52K -$218.5K
COMMON SHARES
Basic Shares Outstanding 15.01M 12.77M shares
Diluted Shares Outstanding 15.01M 12.77M shares

Balance Sheet

Concept 2017 2016 Q4 2016
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.26M $3.930M $3.930M
YoY Change 619.08% 318.09% 318.09%
Cash & Equivalents $28.26M $3.926M $3.930M
Short-Term Investments
Other Short-Term Assets $140.0K $3.000K $40.00K
YoY Change 250.0% 200.0% -50.0%
Inventory
Prepaid Expenses $43.00K
Receivables
Other Receivables
Total Short-Term Assets $28.40M $3.970M $3.970M
YoY Change 615.37% 289.22% 289.22%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $2.000K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $28.40M $3.970M $3.970M
Total Long-Term Assets $0.00 $2.000K $0.00
Total Assets $28.40M $3.972M $3.970M
YoY Change 615.37% 289.41% 289.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $860.0K $244.0K $240.0K
YoY Change 258.33% -17.85% -20.0%
Accrued Expenses $620.0K $125.0K $130.0K
YoY Change 376.92% 38.89% 44.44%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.640M $402.0K $400.0K
YoY Change 310.0% -14.65% -14.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.640M $402.0K $400.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.640M $402.0K $400.0K
YoY Change 310.0% -14.65% -14.89%
SHAREHOLDERS EQUITY
Retained Earnings -$114.3M
YoY Change 2.5%
Common Stock $116.6M
YoY Change 5.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.76M $3.570M $3.570M
YoY Change
Total Liabilities & Shareholders Equity $28.40M $3.972M $3.970M
YoY Change 615.37% 289.79% 289.22%

Cashflow Statement

Concept 2017 2016 Q4 2016
OPERATING ACTIVITIES
Net Income -$7.046M -$1.140M -$2.789M
YoY Change 152.64% 111.11% 323.22%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.641M -$610.0K -$2.124M
YoY Change 71.42% 45.24% 14.19%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $27.38M $5.000M
YoY Change 447.62%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 27.98M 0.000 $5.108M
YoY Change 447.67% 921.6%
NET CHANGE
Cash From Operating Activities -3.641M -610.0K -$2.124M
Cash From Investing Activities 0.000 0.000 $0.00
Cash From Financing Activities 27.98M 0.000 $5.108M
Net Change In Cash 24.33M -610.0K $2.984M
YoY Change 715.48% 45.24% -319.41%
FREE CASH FLOW
Cash From Operating Activities -$3.641M -$610.0K -$2.124M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q2 dei Entity Public Float
EntityPublicFloat
45267296 USD
CY2017 dei Trading Symbol
TradingSymbol
FENCF
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18464706 shares
CY2017Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
167000 USD
CY2016Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
33000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1644000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
402000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
1644000 USD
CY2016Q4 us-gaap Liabilities
Liabilities
402000 USD
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
74515000 USD
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
42134000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121368000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
125000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
855000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
3570000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3972000 USD
CY2016Q4 us-gaap Assets
Assets
3972000 USD
CY2017Q4 us-gaap Assets
Assets
28401000 USD
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3000 USD
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
13000 USD
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
43000 USD
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
128000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3926000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28260000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-114322000 USD
CY2017 us-gaap Revenues
Revenues
0 USD
CY2016 us-gaap Revenues
Revenues
0 USD
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5015000 USD
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2399000 USD
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-6951000 USD
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-2871000 USD
CY2017 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-134000 USD
CY2017 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
47000 USD
CY2016 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
8000 USD
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-95000 USD
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
82000 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-7046000 USD
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-2789000 USD
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1936000 USD
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
472000 USD
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15014000 shares
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12765000 shares
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2016 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
40000 USD
CY2017 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000 USD
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14000 USD
CY2017 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
741000 USD
CY2016 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
88000 USD
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
1517000 USD
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
615000 USD
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3641000 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2124000 USD
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
24334000 USD
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2984000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
942000 USD
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27975000 USD
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5108000 USD
CY2017 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
85000 USD
CY2016 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-33000 USD
CY2017 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
10000 USD
CY2016 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2000 USD
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
611000 USD
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-54000 USD
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
497000 USD
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
33000 USD
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5000000 USD
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
31000 USD
CY2016 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
102000 USD
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27381000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
548000 USD
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000 USD
CY2016 fencf Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
102000 USD
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
563000 USD
CY2017 fencf Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
31000 USD
CY2016 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
72000 USD
CY2017Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
28260000 USD
CY2016Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
3926000 USD
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance Current
DeferredTaxAssetsValuationAllowanceCurrent
23920000 USD
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15014000 shares
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12765000 shares
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15014000 shares
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12765000 shares
CY2017 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2016 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2017Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
167000 USD
CY2016Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
33000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
28260000 USD
CY2017Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
167000 USD
CY2016Q3 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
40000 USD
CY2016Q3 fencf Disposal Of Asset Percentage Of Revenue Sharing
DisposalOfAssetPercentageOfRevenueSharing
0.05 pure
CY2017 fencf Derecognized Of Payable Reversed Into Expenses
DerecognizedOfPayableReversedIntoExpenses
79000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-1771000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1769000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1018000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7046000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2789000 USD
CY2017 fencf Expected Provision For Recovery Of Income Tax
ExpectedProvisionForRecoveryOfIncomeTax
-1867000 USD
CY2016 fencf Expected Provision For Recovery Of Income Tax
ExpectedProvisionForRecoveryOfIncomeTax
-739000 USD
CY2017 fencf Permanent Difference
PermanentDifference
636000 USD
CY2016 fencf Permanent Difference
PermanentDifference
156000 USD
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
328000 USD
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
583000 USD
CY2017 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
0 USD
CY2016 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
0 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-5277000 USD
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.265 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.265 pure
CY2017 fencf Income Tax Reconciliation Tax Credits Other Adjustments
IncomeTaxReconciliationTaxCreditsOtherAdjustments
-3000 USD
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
63000 USD
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-1000 USD
CY2016 fencf Income Tax Reconciliation Tax Credits Other Adjustments
IncomeTaxReconciliationTaxCreditsOtherAdjustments
1000 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance Current
DeferredTaxAssetsValuationAllowanceCurrent
23592000 USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2016Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18411000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18411000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13643000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13643000 shares
CY2017 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
0 USD
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
27381000 USD
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5000000 USD
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="left"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="left"><b>Use of estimates</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="left">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period.&#160;Significant estimates include the valuation of derivative warrant liability and the valuation of stock-based compensation.&#160;Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
843000 USD
CY2016 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0 USD
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23920000 USD
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23592000 USD
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1362000 shares
CY2017Q4 fencf Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber
1603000 shares
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y5M5D
CY2014Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.50
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2017Q4 us-gaap Cash
Cash
275000 CAD
CY2017Q4 us-gaap Cash
Cash
255000 USD
CY2016 us-gaap Description Of Difference Between Reported Amount And Reporting Currency Denominated Amount
DescriptionOfDifferenceBetweenReportedAmountAndReportingCurrencyDenominatedAmount
exchange rate of $CAD/$USD 0.7881
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3964000 shares
CY2017Q4 fencf Proceeds From Registration Payment Arrangement
ProceedsFromRegistrationPaymentArrangement
21200000 USD
CY2017Q4 us-gaap Registration Payment Arrangement Maximum Potential Consideration
RegistrationPaymentArrangementMaximumPotentialConsideration
68800000 USD
CY2017Q3 fencf Number Of Common Shares Registered
NumberOfCommonSharesRegistered
11943000 shares
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
15850000 USD
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1827000 USD
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2195000 USD

Files In Submission

Name View Source Status
0001144204-18-017571-index-headers.html Edgar Link pending
0001144204-18-017571-index.html Edgar Link pending
0001144204-18-017571.txt Edgar Link pending
0001144204-18-017571-xbrl.zip Edgar Link pending
fencf-20171231.xml Edgar Link completed
fencf-20171231.xsd Edgar Link pending
fencf-20171231_cal.xml Edgar Link unprocessable
fencf-20171231_def.xml Edgar Link unprocessable
fencf-20171231_lab.xml Edgar Link unprocessable
fencf-20171231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv488216_10k.htm Edgar Link pending
tv488216_ex23-1.htm Edgar Link pending
tv488216_ex23-2.htm Edgar Link pending
tv488216_ex31-1.htm Edgar Link pending
tv488216_ex31-2.htm Edgar Link pending
tv488216_ex32-1.htm Edgar Link pending
tv488216_ex99-1.htm Edgar Link pending
tv488216_ex99-1logo1.jpg Edgar Link pending
tv488216_img1.jpg Edgar Link pending